{"id":"minoxidil-5-topical-solution","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Scalp irritation"},{"rate":"3-10","effect":"Dryness of scalp or skin"},{"rate":"3-8","effect":"Itching"},{"rate":"1-5","effect":"Unwanted hair growth on adjacent skin"},{"rate":"1-3","effect":"Dermatitis"}]},"_chembl":null,"_dailymed":{"setId":"4dc2850a-9a7e-660f-e063-6294a90afd94","title":"TACRUITF 5% MINOXIDIL WITH BIOTIN TOPICAL SOLUTION (MINOXIDIL) SOLUTION [GUANGZHOU BORDERLESS TECHNOLOGY CO., LTD.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Minoxidil acts as a vasodilator by opening ATP-sensitive potassium channels, which increases cutaneous blood flow to hair follicles and delivers more oxygen and nutrients to the dermal papilla. This stimulation extends the anagen phase of hair growth and may increase hair follicle size, promoting hair regrowth in androgenetic alopecia. The exact mechanism in hair growth remains incompletely understood but involves both vascular and direct follicular effects.","oneSentence":"Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:22.777Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Androgenetic alopecia (male pattern baldness)"},{"name":"Female pattern hair loss"}]},"trialDetails":[{"nctId":"NCT07435012","phase":"PHASE3","title":"Androgenic Alopecia TH07 Clinical Trial","status":"RECRUITING","sponsor":"Triple Hair Inc","startDate":"2026-04","conditions":"Androgenic Alopecia","enrollment":420},{"nctId":"NCT07373054","phase":"NA","title":"Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-11-06","conditions":"Androgenic Alopecia","enrollment":18},{"nctId":"NCT07370519","phase":"PHASE2","title":"Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen People's Hospital","startDate":"2026-01-25","conditions":"Androgenetic Alopecia (AGA)","enrollment":388},{"nctId":"NCT07203599","phase":"PHASE1, PHASE2","title":"A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes","status":"RECRUITING","sponsor":"Shenzhen People's Hospital","startDate":"2025-09-20","conditions":"Androgenic Alopecia","enrollment":59},{"nctId":"NCT04207931","phase":"PHASE4","title":"Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-04-30","conditions":"Central Centrifugal Cicatricial Alopecia (CCCA)","enrollment":250},{"nctId":"NCT06813963","phase":"PHASE4","title":"Minoxidil for Treating White Hair: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Southern Medical University, China","startDate":"2025-02-15","conditions":"Grey Hair","enrollment":100},{"nctId":"NCT07011485","phase":"PHASE2","title":"A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.","status":"ACTIVE_NOT_RECRUITING","sponsor":"PDFE Pharma Innovations FZCO","startDate":"2025-05-14","conditions":"Alopecia, Androgenetic, Baldness, Androgenetic Alopecia (AGA)","enrollment":15},{"nctId":"NCT04721548","phase":"PHASE3","title":"Treatment of Androgenetic Alopecia in Men for 24 Weeks","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2023-03-02","conditions":"Alopecia","enrollment":336},{"nctId":"NCT06501924","phase":"PHASE3","title":"Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss","status":"NOT_YET_RECRUITING","sponsor":"Applied Biology, Inc.","startDate":"2025-01-15","conditions":"Androgenetic Alopecia, Female Pattern Baldness, Male Pattern Baldness","enrollment":516},{"nctId":"NCT06015516","phase":"PHASE1","title":"Bioavailability Clinical Trial of Oral Minoxidil 1 mg","status":"COMPLETED","sponsor":"Industrial Farmacéutica Cantabria, S.A.","startDate":"2024-02-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT05636904","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men","status":"COMPLETED","sponsor":"Dermaliq Therapeutics, Inc.","startDate":"2022-12-05","conditions":"Androgenetic Alopecia","enrollment":120},{"nctId":"NCT06333600","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Topical Vitamin D Analogue in Treatment of Female Pattern Hair Loss","status":"RECRUITING","sponsor":"Sohag University","startDate":"2023-05-20","conditions":"Dermatology, Female Pattern Baldness","enrollment":45},{"nctId":"NCT06218394","phase":"NA","title":"Comparison of Microneedling vs. Autologous Concentrated Growth Factor for the Treatment of Female Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-12-14","conditions":"Androgenetic Alopecia","enrollment":135},{"nctId":"NCT06108193","phase":"PHASE1, PHASE2","title":"Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-07-11","conditions":"Acne Vulgaris","enrollment":26},{"nctId":"NCT06066827","phase":"NA","title":"Hair Regeneration in Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Dr. dr. Lili Legiawati, SpKK(K)","startDate":"2023-08-14","conditions":"Androgenetic Alopecia","enrollment":60},{"nctId":"NCT05989165","phase":"PHASE3","title":"Effectiveness of Combination Therapy of Microneedling and Minoxidil in Androgenetic Alopecia of Indonesian Men","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2023-06-01","conditions":"Androgenetic Alopecia","enrollment":36},{"nctId":"NCT05681897","phase":"NA","title":"Comparing Platelet-Rich Plasma (PRP) Centrifugation Methods on Thrombocyte Concentration and Clinical Improvement of Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2023-02","conditions":"Alopecia, Androgenetic","enrollment":30},{"nctId":"NCT03753113","phase":"PHASE3","title":"Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%","status":"COMPLETED","sponsor":"Farid Masoud","startDate":"2018-11-28","conditions":"Androgenetic Alopecia","enrollment":24},{"nctId":"NCT03535233","phase":"PHASE4","title":"Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2016-03","conditions":"Alopecia Areata","enrollment":40},{"nctId":"NCT02279823","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Intrepid Therapeutics, Inc.","startDate":"2014-10","conditions":"Androgenetic Alopecia","enrollment":95},{"nctId":"NCT02486848","phase":"NA","title":"Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil","status":"WITHDRAWN","sponsor":"Maja Kovacevic, MD","startDate":"2016-06","conditions":"Female Pattern Hair Loss, Androgenetic Alopecia","enrollment":""},{"nctId":"NCT01145625","phase":"PHASE3","title":"Clinical Trial in Females With Female Pattern Hair Loss","status":"COMPLETED","sponsor":"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.","startDate":"2010-06","conditions":"Alopecia","enrollment":322},{"nctId":"NCT00958750","phase":"PHASE3","title":"Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2008-06","conditions":"Androgenetic Alopecia, Female Pattern Hair Loss","enrollment":113}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Regaine®"],"phase":"marketed","status":"active","brandName":"Minoxidil 5% Topical Solution","genericName":"Minoxidil 5% Topical Solution","companyName":"Triple Hair Inc","companyId":"triple-hair-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle. Used for Androgenetic alopecia (male pattern baldness), Female pattern hair loss.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}